Kishvog-MV2 Tablet SR is a combination oral hypoglycemic agent containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake by tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, resulting in reduced postprandial hyperglycemia. The sustained-release formulation of Kishvog-MV2 ensures a gradual and prolonged drug release, optimizing glycemic control while minimizing gastrointestinal side effects commonly associated with immediate-release formulations. This combination therapy targets multiple pathophysiological defects of type 2 diabetes, providing a comprehensive approach to glucose regulation. Kishvog-MV2 is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve target glycemic levels. It should be used under medical supervision, with regular monitoring of blood glucose and renal function. Contraindications include type 1 diabetes, diabetic ketoacidosis, and severe renal or hepatic impairment. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rare hypersensitivity reactions.